EndoGene.Bio
PrivateLast Round
Grant
Jun 15, 2026
Total Funding Raised
$1.95M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EndoGene.Bio operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Grant round in June 2026.
EndoGene.Bio is a biotechnology company that is developing a precision medicine platform using menstrual blood to create non-invasive diagnostics and tools for patient stratification for uterine diseases like endometriosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EndoGene.Bio Comparables
Compare EndoGene.Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NextGen Jane | 79% | |
| Endodiag | 78% | |
| DotLab | 78% |
For institutional investors. Book with your work email.
EndoGene.Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 15, 2026 | ||||
| Seed | Feb 1, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EndoGene.Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Genopole | Seed |
| Hello Tomorrow | Grant |
| Entrepreneurs First | Seed, Accelerator |
| Bpifrance | Seed |
| Frontline Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 15, 2026
$107K grant received from Hello Tomorrow.
- Jan 8, 2026
Monthly visitors grew 1014% MoM, from 81 to 902.
For institutional investors. Book with your work email.
EndoGene.Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EndoGene.Bio's valuation, stock price, and market status.
Is EndoGene.Bio a public or private company?
EndoGene.Bio is a private company.
What is the current stock price of EndoGene.Bio?
EndoGene.Bio is a private company, so its shares have no public market price. Caplight tracks EndoGene.Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EndoGene.Bio worth (valuation)?
Valuation information for EndoGene.Bio is not publicly available.
Can I buy EndoGene.Bio stock?
EndoGene.Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EndoGene.Bio's last funding round?
EndoGene.Bio's most recent funding round was Grant on June 15, 2026.
Who are the main investors in EndoGene.Bio?
Key investors in EndoGene.Bio include Entrepreneurs First.
Will EndoGene.Bio IPO soon?
No public IPO plans have been announced for EndoGene.Bio.
How can I track EndoGene.Bio secondary market activity?
Caplight tracks bids, offers, and trades in EndoGene.Bio's shares on secondary markets.